Comparing two scan methods for imaging neuroblastoma in children
Compares a new PET/CT scan with standard MIBG imaging in children with neuroblastoma.
Plain-language title generated from the registry record
Registry title: Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.
Key facts
- Where
- Paris and Villejuif, FranceSee the 3 sites
- Phase
- Phase 2
Where in France
- Hôpital Armand-TrousseauParis, FranceNo longer taking part
- Institut CurieParis, FranceNo longer taking part
- Gustave RoussyVillejuif, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Curie
- Trial code
- NCT07111117
- Record updated
- 3 September 2025
- Original description
The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.Read full original descriptionShow less
Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma
The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.
Inclusion: Patients with histologically proven neuroblastoma; Relapsed or refractory neuroblastoma; 123I-MIBG avid neuroblastoma (positive 123I-MIBG scintigraphy = showing at least one neuroblastoma lesion (either primary or metastatic) with a significant avidity for 123I-MIBG), performed within 2 weeks to 2 days prior to 18F-MFBG PET/CT; No specific treatment for neuroblastoma between 123I-MIBG scintigraphy and 18F-MFBG PET/CT (PET/CT shall not delay therapeutic management.); Age ≥ 365 days to < 18 years old. For children under 13 months, day of birth should be collected; Weight ≥ 9 kg; Performance Status: Lansky or Karnofsky ≥ 60%; Signed written informed consent by the 2 holders of the parental authority or legal representative(s); Patients covered by a health insurance system.
Exclusion: Pregnant or breastfeeding patient. If indicated, at the investigator's discretion, patients of childbearing potential should have urinary pregnancy test the day of the PET/CT procedure, prior to the MFBG administration; Patient with a parent or legal representative with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid informed consent; Patient inability to comply with protocol requirements without general anesthesia; Any treatment likely to interact with MIBG initiated/modified between scintigraphy with MIBG and PET/CT with MFBG.